Previous 10 | Next 10 |
The first participant has been dosed in a China-based Phase 3 clinical trial, PODIUM-304, evaluating Zai Lab Limited (ZLAB) and Incyte's (INCY) PD-1 inhibitor retifanlimab, combined with platinum-based chemo, in treatment-naïve patients with metastatic non-small cell lung cancer ((NSCLC)...
The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte (INCY) Presents at ESMO Virtual Congress - Slideshow
In a note RBC regards yesterday's selloff in biotechs as an "especially attractive entry point" for leading names such names as Gilead Sciences ([[GILD]] -2.1%), Sarepta Therapeutics ([[SRPT]] -1.8%) and Constellation Pharmaceuticals ([[CNST]] -5.0%).Analysts, led by Brian Abrahams, believe G...
Incyte ( INCY ) is an innovative pharmaceutical company that had its stock price peak at $140.11 in 2017 when it was considered to be a likely acquisition target. Most recently a drug it developed and licensed to Eli Lilly ( LLY ), Olumiant or baricitinib, showed promise as a treatment for CO...
INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of ...
A 94-subject Phase 2 clinical trial, PODIUM-202 , evaluating Incyte's (NASDAQ: INCY ) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemo showed a tr...
Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49% Responses were observed regardless of PD-L1 status, presence of liver metastases or HIV+ stat...
- Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the companies intend to host a con...
Mergers have been lagging Mergers for 2020 have vastly lagged last year. This has been a cause of concern for me in judging the health of the stock market. For the raison d'etres of Wall Street is not to make us rich, it's to create a source of equity capital to build companies. Our role...
Eli Lilly (NYSE: LLY ) announces positive preliminary results from an NIAID-sponsored clinical trial, ACTT-2 , evaluating the combination of baricitinib and Gilead Sciences' (NASDAQ: GILD ) remdesivir in more than 1,000 hospitalized COVID-19 patients. More news on: Eli Lilly and Com...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...